LuciTirPen (Tirzepatide) 7.5mg/0.5mL Pre-filled Pen

Product Overview
LuciTirPen contains the active ingredient Tirzepatide, a novel GLP-1/GIP dual receptor agonist designed as a convenient, once-weekly subcutaneous injection. It is indicated for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbid condition.

Tirzepatide works by mimicking two natural hormones (GIP and GLP-1) that regulate appetite, reduce hunger, and increase feelings of fullness. As a dual-agonist, it offers a more comprehensive approach to metabolic health compared to single-pathway GLP-1 agonists.

The pre-filled pen design allows for easy, at-home administration under medical guidance, with a single-patient-use device that requires no separate needle handling.

Key Features & Benefits
Once-Weekly Injection: One pre-filled pen per week. No daily dosing required.

Pre-filled Pen: Ready to use with a simple, user-friendly design.

Dual-Action Mechanism: Targets both GIP and GLP-1 receptors for enhanced appetite control and blood sugar regulation.

Clinically Proven Efficacy: In the SURMOUNT-1 clinical trial, the 7.5mg dose achieved an average weight loss of 17.2% (38.2 lbs) over 72 weeks.

Flexible Administration: Can be injected into the abdomen, thigh, or upper arm. Rotate injection sites to reduce irritation.

Dosage and Administration
This product is LuciTirPen 7.5mg/0.5mL pre-filled pen. The recommended titration schedule is as follows:

Starting Dose: 2.5mg once weekly for 4 weeks (initial adaptation)

Maintenance Dose (Level 1): 5mg once weekly for at least 4 weeks

Maintenance Dose (Level 2): 7.5mg once weekly for at least 4 weeks

Further Titration: Dose may be increased to 10mg, 12.5mg, or up to the maximum of 15mg based on individual tolerance and treatment response.

Important Administration Guidelines:

Do not share the pen with other people, even if the needle is changed.

Inject once weekly on the same day each week.

Can be taken at any time of day, with or without food.

If a dose is missed, it can be taken within 96 hours (4 days). If more than 96 hours have passed, skip the missed dose and resume the regular weekly schedule.

Do not take two doses within 3 days of each other.

Product Specifications
Item Details
Product Name LuciTirPen
Active Ingredient Tirzepatide 7.5mg per 0.5mL
Dosage Form Solution for injection in pre-filled pen
Pack Size 1 Pre-filled Pen per box
Administration Subcutaneous injection once weekly
Prescription Status Rx Only (Requires a prescription)
Manufacturer Lucius Pharmaceuticals
Safety Information
Warnings and Precautions
Thyroid C-Cell Tumors: Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis: Discontinue use if severe abdominal pain is suspected.

Hypoglycemia: Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia.

Pregnancy and Breastfeeding: May cause fetal harm. Discontinue if pregnancy is recognized.

Drug Interactions: Caution with oral contraceptives, NSAIDs, and diuretics.

Common Side Effects
The most common adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal discomfort, injection site reactions, and reduced appetite. These symptoms are usually mild to moderate and tend to improve over time.

Medical Disclaimer: This information is for product description purposes only and is not intended as medical advice. Always consult your healthcare provider before starting any prescription medication. This is a Rx Only product and requires a valid prescription.